Talk:Sugammadex

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sugammadex.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Phase III data

Any preliminary phase 3 data available for sharing? Mdw346 15:33, 7 December 2006 (UTC)MDW 07 Dec.06[reply]

Sept 16, 2007: —Preceding unsigned comment added by Mdw346 (talk • contribs) 12:01, 16 September 2007 (UTC) Preliminary Phase III and updated Phase II data has been released in Europe June 9-12, 2007 at the European Society of Anaesthesiology Munich, Germany. No surprises- continued successful, effective, dose-dependent fast time to reversal of all levels of neuromuscular blockade induced by rocuronium and vecuronium. Shallow level blockade induced by pancuronium was effectively conducted by Decoopman M, et al. Referenced in "sugammade" wiki article. Pediatric, elderly, cardiac disease, pulmonary disease, and renal disease patients also successfully treated with sugammadex (ESA mtg. June 2007. ASA mtg. October 2007). Concerns of QTc prolongation by sugammadex addressed by de Kam PJ, et al (Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007;107:A1580)The authors concluded sugammadex did not prolong the QT interval based on ICH-E14 guideline criteria.[reply]

Selective Relaxant Binding Agent

Started a wiki subject page "Selective Relaxant Binding Agent"[1] and a discussion page. It could use help and maybe a link from "SRBA" in this article. Good idea? Thoughts? —Preceding unsigned comment added by Mdw346 (talk • contribs) 12:40, 16 September 2007 (UTC)[reply]

WikiProject class rating

This article was automatically assessed because at least one WikiProject had rated the article as start, and the rating on other projects was brought up to start class. BetacommandBot 16:31, 10 November 2007 (UTC)[reply]

Where is "Sugammadex encaps rocuronium.jpg" image?

I'm translating this page to catalan wikipedia and I'm unable to find it in Commons (Sugammadex encaps rocuronium.jpg). Where is it? How can I get it? Replay to: http://ca.wikipedia.org/wiki/Usuari:Tabalot Thanks —Preceding unsigned comment added by 85.58.137.14 (talk) 20:11, 14 March 2009 (UTC)[reply]

Talk:Sugammadex

Phase III data

Selective Relaxant Binding Agent

WikiProject class rating

Where is "Sugammadex encaps rocuronium.jpg" image?

Navigation menu

Search